|Drugs of the Future|
| || |
|Drugs Fut 2007, 32(2): 123|
Copyright 2007 Clarivate Analytics
Davies, S.L., Serradell, N., Bolos, J., Bayes, M.
|The bicyclam derivative plerixafor hydrochloride (AMD-3100, Mozobil) was originally discovered as a potent and selective anti-HIV agent; however, problems with unexpected cardiac disturbances led AnorMED (now part of Genzyme) to discontinue its development. Subsequent studies identified plerixafor as the first potent and selective nonpeptide chemokine CXCR4 (SDF-1) receptor antagonist and as a result development has focused on its use for mobilizing hematopoietic stem cells (HSCs) for transplantation as a rescue therapy after high-dose myeloablative therapy. In vitro and in vivo studies have demonstrated that plerixafor effectively mobilizes HSCs. Clinical trials have confirmed safety and tolerability and its ability to improve cell mobilization. Plerixafor has reached phase III clinical development for improving the outcome of stem cell transplantation in non-Hodgkin's lymphoma (NHL) and multiple myeloma (MM) patients.|
Full Text: HTML, PDF
| || |